ME00674B - Disperzioni preparati sa sadržajem inhibitora lipaza - Google Patents

Disperzioni preparati sa sadržajem inhibitora lipaza

Info

Publication number
ME00674B
ME00674B MEP-2008-908A MEP90808A ME00674B ME 00674 B ME00674 B ME 00674B ME P90808 A MEP90808 A ME P90808A ME 00674 B ME00674 B ME 00674B
Authority
ME
Montenegro
Prior art keywords
formulations containing
lipase inhibitors
dispersion formulations
containing lipase
lipase inhibitor
Prior art date
Application number
MEP-2008-908A
Other languages
English (en)
French (fr)
Inventor
Paul Hadvary
Hans Lengsfeld
Smidt Passchier Christiaan De
Tomas Rades
Hans Steffen
Joseph Tardio
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8238990&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME00674(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ME00674B publication Critical patent/ME00674B/me
Publication of MEP90808A publication Critical patent/MEP90808A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Ovaj pronalazak se odnosi na farmaceutske smeše koje sadrže najmanje jedan inhibitor lipaza, prvenstveno inhibitor gastrointestinalnih i pankreasnih lipaza, npr. orlistat, najmanje jedn površinski aktivnu supstancu i najmanje jedan dispergent.
MEP-908/08A 1999-09-13 2000-09-11 Dispersion formulations containing lipase inhibitors MEP90808A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99118180 1999-09-13
PCT/EP2000/008858 WO2001019340A1 (en) 1999-09-13 2000-09-11 Dispersion formulations containing lipase inhibitors

Publications (2)

Publication Number Publication Date
ME00674B true ME00674B (me) 2011-12-20
MEP90808A MEP90808A (en) 2011-12-20

Family

ID=8238990

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-908/08A MEP90808A (en) 1999-09-13 2000-09-11 Dispersion formulations containing lipase inhibitors

Country Status (39)

Country Link
US (3) US20030181512A1 (me)
EP (1) EP1216025B1 (me)
JP (1) JP4217016B2 (me)
KR (1) KR100572434B1 (me)
CN (1) CN1197551C (me)
AR (1) AR025587A1 (me)
AT (1) ATE333866T1 (me)
AU (1) AU769415B2 (me)
BR (2) BRPI0013939B1 (me)
CA (1) CA2383916C (me)
CO (1) CO5180587A1 (me)
CY (1) CY1106180T1 (me)
CZ (1) CZ301901B6 (me)
DE (1) DE60029602T2 (me)
DK (1) DK1216025T3 (me)
EG (1) EG24117A (me)
ES (1) ES2267563T3 (me)
HK (1) HK1049966A1 (me)
HR (1) HRP20020205B1 (me)
HU (1) HU228858B1 (me)
IL (1) IL148494A0 (me)
JO (1) JO2386B1 (me)
MA (1) MA26818A1 (me)
ME (1) MEP90808A (me)
MX (1) MXPA02002034A (me)
MY (1) MY130200A (me)
NO (1) NO331906B1 (me)
NZ (1) NZ517545A (me)
PE (1) PE20010595A1 (me)
PL (1) PL199870B1 (me)
PT (1) PT1216025E (me)
RS (1) RS50422B (me)
RU (1) RU2239428C2 (me)
SI (1) SI1216025T1 (me)
TR (1) TR200200606T2 (me)
TW (1) TWI243060B (me)
UY (1) UY26338A1 (me)
WO (1) WO2001019340A1 (me)
ZA (1) ZA200201518B (me)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL204443B1 (pl) * 2000-07-28 2010-01-29 Hoffmann La Roche Kompozycja farmaceutyczna zawierająca inhibitor lipazy, sposób wytwarzania kompozycji farmaceutycznej, zestaw do leczenia otyłości, zastosowanie kompozycji farmaceutycznej oraz zastosowanie orlistatu i substancji wiążącej kwasy żółciowe
US6730319B2 (en) * 2001-06-06 2004-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions having depressed melting points
US20030027786A1 (en) 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
US8372430B2 (en) 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
FI20045076A (fi) * 2004-03-15 2005-09-16 Bioferme Oy Funktionaalinen elintarvike
RU2429850C2 (ru) * 2005-04-15 2011-09-27 Кларус Терапьютикс, Инк. Фармацевтические системы доставки для гидрофобных лекарственных средств и композиций, их содержащих
KR100910000B1 (ko) * 2005-05-13 2009-07-29 씨제이제일제당 (주) 리파아제 저해제 함유 약학 조성물
US20090208584A1 (en) * 2005-06-09 2009-08-20 Tomohiro Yoshinari Solid preparation
KR100669497B1 (ko) * 2005-08-17 2007-01-16 보람제약주식회사 안정성과 용출률이 뛰어난 약리학적 조성물 및 그 제조방법
WO2007033522A1 (fr) * 2005-09-21 2007-03-29 Shenzhen Tys R & D Co., Ltd. Formulation de gélule contenant de la moxifloxacine et son procédé de préparation
KR101252635B1 (ko) 2006-04-20 2013-04-10 (주)아모레퍼시픽 리파아제 저해제 및 친유성 오일흡수제를 포함하는 약학조성물 및 이로부터 제조된 경구 투여용 제제
TR200607613A2 (tr) * 2006-12-29 2008-07-21 NOBEL İLAÇ SAN.ve TiC.A.Ş. Lipaz inhibitörü içeren farmasötik formülasyonlar
EP1970051A1 (en) * 2007-03-14 2008-09-17 Merz Pharma GmbH & Co.KGaA Use of an aqueous micro-emulsion for the preparation of a formulation for the treatment of adipose diseases
KR101439470B1 (ko) * 2007-05-22 2014-09-16 한미사이언스 주식회사 오를리스타트 및 대변 연화제를 포함하는 비만의 예방 또는치료용 조성물
ATE477820T1 (de) * 2007-09-12 2010-09-15 Mader S R L Pharmazeutische zusammensetzungen zur oralen verabreichung bei der behandlung von adipositas- patienten
EP2044930A1 (en) * 2007-10-01 2009-04-08 Nestec S.A. Composition for controlling lipase catalyzed reactions
PL216542B1 (pl) 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
WO2010042499A1 (en) * 2008-10-06 2010-04-15 Banner Pharmacaps, Inc. Stable solutions of orlistat for pharmaceutical dosage forms
KR20100075260A (ko) * 2008-12-24 2010-07-02 주식회사종근당 리파아제 저해제의 부작용 개선을 위한 신규한 약제학적 조성물
BRPI0901602B8 (pt) 2009-04-03 2021-05-25 Ems S/A formulação farmacêuticas
ITRM20120331A1 (it) 2012-07-12 2014-01-13 Guidotti & C Spa Labor Composizioni pediatriche orali liquide contenenti nepadutant.
WO2016166767A1 (en) * 2015-04-14 2016-10-20 Zim Laboratories Limited Pharmaceutical formulation comprising low melting, highly lipophilic drugs
CN106310287B (zh) * 2015-06-25 2019-03-19 山东省药学科学院 新利司他药用组合物及其制备方法
MY196635A (en) * 2018-06-22 2023-04-25 Sime Darby Plantation Intellectual Property Sdn Bhd Method For Reducing Formation of Free Fatty Acids in Plants
CN115105476B (zh) * 2021-03-23 2023-11-14 山东新时代药业有限公司 一种奥利司他冻干口服制剂及其制备工艺
CN114983938A (zh) * 2022-05-19 2022-09-02 广东嘉博制药有限公司 一种奥利司他口服复合乳液及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
DE3887179T2 (de) * 1987-03-02 1994-06-16 Brocades Pharma Bv Pharmazeutische Zusammensetzung, pharmazeutisches Granulat und Verfahren zu ihrer Herstellung.
CA2128044C (en) 1993-08-05 2007-02-20 Klaus-Dieter Bremer Pharmaceutical compositions comprising a glucosidase and/or amylase inhibitor, and a lipase inhibitor
IT1282673B1 (it) 1996-02-23 1998-03-31 Ist Naz Stud Cura Dei Tumori Derivati della camptotecina e loro uso come agenti antitumorali
WO1998008490A1 (en) 1996-09-01 1998-03-05 Pharmos Corporation Solid coprecipitates for enhanced bioavailability of lipophilic substances
US5891469A (en) * 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
KR100479968B1 (ko) 1997-02-05 2005-03-30 에프. 호프만-라 로슈 아게 위장 리파아제 억제제의 용도
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
ATE263558T1 (de) 1998-08-14 2004-04-15 Hoffmann La Roche Lipasehemmer und chitosan enthaltende pharmazeutische zusammensetzungen
JP3774118B2 (ja) 1998-08-14 2006-05-10 エフ．ホフマン−ラ ロシュ アーゲー リパーゼ阻害剤を含む製薬学的組成物
US6368622B2 (en) * 1999-01-29 2002-04-09 Abbott Laboratories Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption

Also Published As

Publication number Publication date
NO331906B1 (no) 2012-04-30
HU228858B1 (en) 2013-06-28
AU769415B2 (en) 2004-01-29
YU17202A (sh) 2006-01-16
KR100572434B1 (ko) 2006-04-18
CO5180587A1 (es) 2002-07-30
CY1106180T1 (el) 2011-06-08
PT1216025E (pt) 2006-12-29
AU7286300A (en) 2001-04-17
WO2001019340A1 (en) 2001-03-22
NO20021204L (no) 2002-03-12
MEP90808A (en) 2011-12-20
HRP20020205A2 (en) 2004-04-30
EG24117A (en) 2008-07-06
DE60029602D1 (de) 2006-09-07
CN1373656A (zh) 2002-10-09
ATE333866T1 (de) 2006-08-15
HUP0202737A2 (hu) 2003-01-28
ES2267563T3 (es) 2007-03-16
CN1197551C (zh) 2005-04-20
ZA200201518B (en) 2003-07-30
CZ20021276A3 (cs) 2003-04-16
KR20020063852A (ko) 2002-08-05
RS50422B (sr) 2009-12-31
AR025587A1 (es) 2002-12-04
BRPI0013939B1 (pt) 2017-07-18
BR0013939A (pt) 2002-05-14
US20040175420A1 (en) 2004-09-09
HRP20020205B1 (en) 2011-06-30
UY26338A1 (es) 2000-10-31
HUP0202737A3 (en) 2005-01-28
JP2003509357A (ja) 2003-03-11
EP1216025B1 (en) 2006-07-26
CA2383916C (en) 2009-01-20
PL356174A1 (en) 2004-06-14
RU2239428C2 (ru) 2004-11-10
CZ301901B6 (cs) 2010-07-28
NZ517545A (en) 2003-11-28
MXPA02002034A (es) 2002-08-20
PL199870B1 (pl) 2008-11-28
CA2383916A1 (en) 2001-03-22
IL148494A0 (en) 2002-09-12
US20110275706A1 (en) 2011-11-10
HK1049966A1 (en) 2003-06-06
DE60029602T2 (de) 2007-07-26
EP1216025A1 (en) 2002-06-26
TR200200606T2 (tr) 2002-07-22
DK1216025T3 (da) 2006-10-30
MA26818A1 (fr) 2004-12-20
MY130200A (en) 2007-06-29
NO20021204D0 (no) 2002-03-12
SI1216025T1 (sl) 2006-12-31
JP4217016B2 (ja) 2009-01-28
JO2386B1 (en) 2007-06-17
US20030181512A1 (en) 2003-09-25
PE20010595A1 (es) 2001-05-26
TWI243060B (en) 2005-11-11
US8012494B2 (en) 2011-09-06

Similar Documents

Publication Publication Date Title
ME00674B (me) Disperzioni preparati sa sadržajem inhibitora lipaza
EA199900373A2 (ru) Фармацевтические композиции
TR199801336T2 (xx) Dezenfekte edici bile�imler.
BR0317715A (pt) Composições e processos de uso de collajolie
ECSP034462A (es) Composiciones farmaceuticas de inhibidores de la proteina de transferencia de colesteril ester
CA2340052A1 (en) Pharmaceutical compositions containing lipase inhibitors and chitosan
CY1106247T1 (el) Θειοφαινο- και θειαζολοσουλφοναμιδες ως αντινεοπλαστικοι παραγοντες
AU5414000A (en) Compounds
DK1273299T3 (da) Minoxidilinindeholdende praparater
TWI256288B (en) Liquid formulations
BR0116166A (pt) Inibidores da serina protease
DE60019100D1 (de) Im wesentlichen ölfreie cyclosporin zusammensetzungen
NO20030772L (no) Fremgangsmate til fremstilling av vannfritt azitromycin
TR200102448T2 (tr) COPD tedavisi için kontrollu salma formülasyonu.
NZ502133A (en) Method of enhancing bioavailability of fexofenadine and its derivatives
MY128164A (en) Compounds
DK1198225T3 (da) Epothilonsammensætninger
MXPA03000860A (es) Inhibidores de cdc25-fosfatasas.
ATE317384T1 (de) Lta4 hydrolase-hemmer
DE60102704D1 (de) Trioxepan verbindungen
HN2000000089A (es) Polimorfos de un diclohidrato cristalino de azobiciclo (2,2,2) oct - 3 - ilamina y sus composiciones farmaceuticas.
UA32223A (uk) Сонцезахисні окуляри
HN2000000084A (es) Inhibidores de metaloproteasa.
UA30885A (uk) Мастило для форм
ES2184593A1 (es) Composiciones que comprenden lisina y compuestos de ascorbato para el tratamiento y la prevencion de enfermedades cardiovasculares.